

Special Issue

Impact of Drug Transporter Gene Variation on Pharmacokinetics and Clinical Outcomes in Chronic Disease Therapy

Message from the Guest Editors

We are actively soliciting papers on the following topics:

(1) Functional and regulatory consequences of transporter variants (common/rare, haplotypes) on PK/PD and exposure–response. (2) Clinical association studies linking genotypes/phenotypes with efficacy, toxicity, and hard outcomes in chronic disease cohorts. (3) Population PK and PBPK modeling incorporating transporter genotype, disease state (e.g., CKD, NAFLD), and drug–drug–gene interactions. (4) Real-world evidence: EHR/biobank analyses, multi-ancestry/sex-stratified effects, and health-equity implications. (5) Co-determinants of variability: Comorbidities, inflammation, organ impairment, polypharmacy, and longitudinal therapy changes. (6) Implementation science: Clinical decision support, guideline translation (CPIC/DPWG), cost–utility analyses, and practice frameworks. (7) Methodological advances: In vitro/in vivo models, transporter phenotyping/probes, imaging, and bioanalytical workflows.

Guest Editors

Prof. Dr. Fernando De Andrés

1. Faculty of Pharmacy, Department of Analytical Chemistry and Food Technology, University of Castilla-La Mancha, 02071 Albacete, Spain
2. Regional Institute of Applied Scientific Research IRICA, 13071 Ciudad Real, Spain

Dr. Pedro Dorado

1. Department of Medical-Surgery Therapeutics, Pharmacology Section, Faculty of Medical and Health Sciences, University of Extremadura, Av. de Elvas s/n., 06071 Badajoz, Spain
2. Personalized Medicine and Mental Health Unit (MEPER), Extremadura Biosanitary University Research Institute of Extremadura (INUBE), Av. de Elvas s/n., 06080 Badajoz, Spain

Deadline for manuscript submissions

25 May 2026



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/257953

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)